These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8434965)

  • 21. Comparative evaluation of two administration schedules of cis-dichlorodiammineplatinum (DDP) in ovarian and head and neck cancers: a CMEA chemotherapy group study.
    Mechl Z; Kerpel-Fronius S; Decker A; Gorbunova VA; Gürtler R; Hindy I; Krafft W; Kolarić K; Nekulova M; Sopkova B
    Neoplasma; 1987; 34(1):37-43. PubMed ID: 3561604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intra-arterial chemotherapy of ovarian cancer using a subcutaneously embedded reservoir--a case showing remarkable response to intermittently repeated low-dose intra-arterial infusion chemotherapy].
    Izawa H; Nomura S; Inoue H
    Gan To Kagaku Ryoho; 1988 Jan; 15(1):147-50. PubMed ID: 3337522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer.
    Imada T; Sairenji M; Suda T; Yamamoto Y; Amano T; Motohashi H
    Hepatogastroenterology; 1999; 46(25):594-600. PubMed ID: 10228867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
    Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
    Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy].
    Kaneyasu Y; Okawa MK; Kokubo N; Takemoto M; Karasawa K; Fukuhara N; Toda J; Okawa T
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1486-93. PubMed ID: 8854787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adjuvant chemotherapy of paclitaxel plus carboplatin in uterine corpus cancer--comparison with cisplatin, adriamycin plus cyclophosphamide].
    Tanase Y; Kawaguchi R; Haruta S; Kanayama S; Yamada Y; Kobayashi H
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):945-50. PubMed ID: 16835485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Toxicity and efficacy of chemotherapy dependent on circadian time of cytostatic drug administration].
    Zuchowska-Vogelgesang B; Pernal J; Zemełka T
    Przegl Lek; 1996; 53(12):870-3. PubMed ID: 9163011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intra-arterial infusion of CDDP in advanced gastrointestinal cancer (combination of general chemotherapy)].
    Kurihara A; Abe J; Yamane T; Odachi T; Sumikawa M; Ikeda Y; Murata Y; Ishiguro M; Fukuma K
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):586-9. PubMed ID: 3954380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis.
    Neijt JP; Engelholm SA; Witteveen PO; Tuxen MK; Sørensen PG; Hansen M; Hirsch F; Sessa C; de Swart C; van Houwelingen HC; Lund B; Hansen SW
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-36-S15-39. PubMed ID: 9346220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
    Li M; Huang X
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: relationship to nausea and vomiting.
    Hursti TJ; Börjeson S; Hellström PM; Avall-Lundqvist E; Stock S; Steineck G; Peterson C
    Scand J Gastroenterol; 2005 Jun; 40(6):654-61. PubMed ID: 16036525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study.
    de Oliveira CF; Lacave AJ; Villani C; Wolff JP; di Re F; Namer M; Maskens A; George M; Dalesio O; Rotmensz N
    Eur J Gynaecol Oncol; 1990; 11(5):323-30. PubMed ID: 2097149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.